Good day, ladies and gentlemen. Welcome to the Aziyo Biologics Q1 2023 financial results conference call. If you know you would like to ask a question, please press star one on your telephone keypad to join the queue. Please be advised that today's conference call is being recorded. I would now like to hand the conference call over to Matt Steinberg, FINN Partners.
Thank you, operator, and thank you all for participating in today's call. Earlier today, Aziyo released financial results for the quarter ended March 31st, 2023. A copy of the press release is available on the company's website. Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws, which are pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that do not relate to matters of historical facts or relate to expectations or predictions of future events, results, or performance are forward-looking statements. All forward-looking statements, including, without limitation, those relating to our operating trends and future financial performance, are based upon our current estimates and various assumptions.
These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the Risk Factors section on our public filings with the SEC, including Aziyo's annual report on Form 10-Q for the quarter ended March 31st, 2023, to be filed with the SEC, accessible on the SEC's website at www.sec.gov. Such factors may be updated from time to time in Aziyo's other filings with the SEC. The conference call contains time-sensitive information and is accurate only as of the live broadcast today, May 10th, 2023.
Aziyo Biologics disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. Also, during this presentation, we refer to gross margin excluding intangible asset amortization, which is a non-GAAP financial measure. A reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure is available in the company's financial results release for the Q1 ended March 31, 2023, which is accessible on the SEC's website and posted on the investor page of the Aziyo website at www.aziyo.com. With that, I will turn the call over to Aziyo's CEO, Randy Mills.
Thank you, Matt. Welcome to our Q1 2023 earnings call. Today, I'll start with an overview of recent highlights. I will then describe how our efforts fit into the overall strategy for Aziyo. Matt Ferguson, our CFO, will provide details and context for our financial results. Lastly, I'll wrap up with the priorities for the company moving forward. After that, we'll open the line for your questions. We have a lot of ground to cover, so let's jump in. First, it would be hard to miss the exceptional financial performance delivered by our businesses. Sales were up 14% to a record $13.1 million for the quarter, and this top-line growth was seen across all of our four businesses. Furthermore, we saw substantial improvement in gross margin, up 11 points year-over-year to 49%.
The improvement in gross margin is largely attributed to process improvements made by our operations team, led by Erica Elchin. Recall, Erica was one of the leadership changes that we made in the H2 of last year, and the efforts of her and her team are starting to produce some really impressive results. Next up, we made great progress on the business development front, which included creating a partnership with LeMaitre Vascular to distribute our cardiovascular portfolio. With this deal, we gain access to LeMaitre's expert 58-person sales team dedicated to the needs of the cardiovascular surgeon, increasing coverage approximately five-fold. Similarly, we are now operationalizing our non-exclusive distribution partnership with Sientra, a leader in breast reconstruction surgery for our best-in-class product, SimpliDerm. Like with LeMaitre, this partnership greatly expands sales coverage for SimpliDerm with the addition of Sientra's 55 sales professionals.
Again, approximately a five-fold increase over our current coverage. These transactions enable us to improve patient access and outcome, at the same time, they increase our commercial footprint in a capital efficient manner. Lastly, we've made progress with FDA. Following the receipt of our NSE letter for CanGaroo RM, we were granted a meeting with the review teams from both the Center for Devices and the Center for Drugs, as CanGaroo RM is regulated as a combination product at FDA. The meeting was productive, with the results being a clear understanding of the additional information requested by the agency for the resubmission of CanGaroo RM 510(k). The request is limited to in vitro quality control testing and importantly, does not require the generation of any animal or human data.
Our R&D teams are laser focused on generating this information and are confident we will be able to provide the agency with the required information. Let's put some this strong performance into the context of our overall strategy for Aziyo. At Aziyo, our mission is to humanize medical devices for better patient outcomes. We believe that a very practical application of regenerative medicine is improving the interface between the medically essential device and the patient that it's intended to treat. Complications that arise at the device-patient interface, whether it be from movement or erosion or fibrosis or infection, is an enormous problem and also represents a massive opportunity.
When you just look at the surgical procedures that CanGaroo and SimpliDerm address, each year there are over 90,000 complications so severe that they require surgical reintervention, at a cost to the healthcare system of seven and a half billion dollars. That's not to mention the very real morbidity and mortality that the patient and their family experience. Here's what we think is really exciting. We're developing technology that combines the proven benefits of a biologically based material with therapeutic delivery to create the drug-eluting biologic. The combination of these two can produce synergistic effects, that's because there are so many therapeutically relevant drugs that are also highly protein-bound, keeping them at the site inactive much longer than you would get with simple drug elution. We saw this effect rather dramatically in our preclinical studies for CanGaroo RM.
Weeks after the drug elution was complete, the biologic pouch still had the ability to kill a six log challenge of pathogenic bacteria. We're starting with relatively simple therapeutics here, like antibiotics with CanGaroo RM, but we really think that's just the tip of the iceberg. Now let's look at how we're putting this technology to work across our different businesses. Aziyo is organized into four business units according to the markets served. These are CanGaroo, which is an envelope technology used primarily with pacemaker implantation today, but it also has indications in neurostimulation and the like. SimpliDerm, our acellular dermis technology, which is used in breast reconstruction. Cardiovascular, which leverages porcine-derived extracellular matrix for cardiac and vascular surgery. Lastly, Orthobiologics, our allograft business that's focused on spine and orthopedics surgery.
Our CanGaroo and SimpliDerm businesses are, and we believe will continue to be, high growth opportunities for us. They are also two product lines that best leverage our drug-eluting technology moving forward. Focusing on CanGaroo for a minute, we saw very healthy top line and gross margin improvements. This is a product that we distribute through two channels. One is through a proprietary sales force, the other is through our distribution partner, Boston Scientific. CanGaroo has tremendous value, both with and without antibiotic supplementation. There has been some great clinical work published that shows the benefit of CanGaroo, particularly in the subcutaneous defibrillator placement, where migration and fibrosis are a real threat to efficacy. There's a new paper out in JACC, it's the Journal of the American College of Cardiology, demonstrating this effect. Look for it.
We also have some exciting data being presented at the upcoming Annual Heart Rhythm Society meeting in New Orleans. We will be there from May 19th through the 21st at Booth 319. If you're there, stop by. We would love to see you. Again, all of this great activity is on our currently marketed version of CanGaroo without antibiotics. As mentioned in the opening, we are preparing for the resubmission of CanGaroo RM, our pouch product that elutes the antibiotics rifampin and minocycline. I know the question that everyone wants to know: When will we be ready to resubmit to FDA? What I can tell you now is that we are confident we can produce a high quality submission, and two, it will be filed within the calendar year. We will provide further updates as we gain more specificity. Moving to SimpliDerm.
Here we saw top line growth of 40%. Surgeons love this product. We sell SimpliDerm through our own distributor network, and as recently announced, we have added breast implant manufacturer Sientra as a partner. This makes a lot of sense for both organizations, as breast implant surgery frequently requires the use of an acellular dermal product. We also saw very nice increase in gross margin on SimpliDerm, resulting from process improvements in manufacturing. Cost of goods reduction on SimpliDerm is an important goal for us, and we believe these improvements, along with volume increases we expect to see with the Sientra partnership, will increase the profitability of this line substantially. On the other side of the house, we have our more mature businesses in terms of revenue growth potential, but which are still great cash producers for the organization. These are our cardiovascular and Orthobiologics businesses.
Yet, even here, we saw solid growth this quarter. Our cardiovascular business was up 12%, and our new partnership with LeMaitre will open up our product representation significantly, adding 58 direct sales reps to our current coverage. In this new model, we sell product to LeMaitre in bulk at a transfer price that is approximately about half of what we're recognizing in the end market. Despite that, going forward, we estimate that we'll realize a gross margin of approximately 60% on what should be much higher volumes, and again, with virtually no selling cost. Therefore, as with our other strategic moves, we expect that this partnership will improve our profitability and our cash flow. Our final business unit is Orthobiologics. It is our largest in terms of revenue, and here we've made remarkable progress under new leadership.
For the period, sales grew 7% to $6.7 million and gross margin improved 14 points. These improvements are driven by strong demand for the product and by process improvements the team has implemented along the way, both of which we think are likely to continue. All in all, a very strong quarter. With that, I'll stop talking and turn it over to Matt to give us, some financial highlights.
Okay. Thanks, Randy. We are very pleased with our Q1 results, highlighted by record net sales and gross profit. As Randy mentioned, we achieved 14% growth for the Q1 of 2023, net sales of $13.1 million. The increase was driven by growth across all four business segments, led by our SimpliDerm and CanGaroo product lines. Gross profit for the Q1 of 2023 was $6.3 million, resulting in a gross margin of 49%, up 11 percentage points compared to the prior- year- period. On a non-GAAP basis, excluding amortization of intangibles, which may be viewed as more indicative of our operating performance, gross margin grew to 55%, up from 45% in the Q1 of 2022.
We saw operational gains at both of our manufacturing sites, with the greatest impact coming from our Orthobiologics and Women's Health business units. Total operating expenses were $12.7 million for the Q1 of 2023, compared to $11.2 million in the corresponding prior- year- period. The increase was primarily due to increased non-cash accruals related to the 2021 recall of our FiberCel product. With the gains in gross profit and the somewhat higher operating expenses in the quarter, our Q1 net loss was only slightly changed from the prior- year- period, coming in at $8.0 million for Q1 of this year, compared to $8.1 million in the year ago quarter. As of March 31, 2023, our cash position was $11.8 million.
This reflects cash usage of $5.2 million for the quarter. Based on a variety of factors, the partnerships we've implemented, continued organic growth, and a variety of other efficiency measures we've implemented, we expect this burn rate to come down significantly during the remainder of the year. We'll see some effect in Q2, and by the H2 of the year, we expect cash burn to be at roughly half of recent levels. In other words, in the range of $2 million-$3 million per quarter for Q3 and Q4 of this year. I'd also like to remind everyone that we're fortunate to have a committed base of shareholders, chief among them, HighCape Partners, who is one of the founders of the company and continues to be our largest shareholder.
We very much appreciate that HighCape remains actively involved in the company and committed to our long-term success and increasing shareholder value. With that, I'll hand it back to Randy before we take questions.
Thank you, Matt. I'd like to finish up with a summary of our priorities moving ahead. First, we are continuing to drive top line growth, particularly in our CanGaroo and SimpliDerm lines. To this end, we are strengthening our partnership with Boston Scientific by building awareness around the unique synergies CanGaroo offers Boston CRM products, specifically, their subcutaneous defibrillator. With SimpliDerm, we are continuing to drive sales through our own distribution network and are working aggressively with Sientra to get their sales team up and running. We are also doing the same with LeMaitre, looking to set a strong trajectory out of the gate for our cardiovascular products. Our second point of focus is improving cash flow. We want the cost of goods improvements we have made to stick and to serve as a base for even better margins going forward.
As Matt pointed out, we're doing a nice job reducing operating expense and are targeting to have our cash burn rate cut in half in the second part of the year. We're still not done with business development activities. We've had some solid wins already this year, but we look forward to capitalizing on additional opportunities, specifically around our Orthobiologics and CanGaroo businesses, which could further improve our cash position. Our third point of focus is the resubmission of CanGaroo RM. Our regulatory and R&D teams, led by Dr. Michelle Williams, are hard at work generating the data the agency needs for resubmission, and we look forward to providing you with updates as our progress unfolds.
We kicked off 2023 on a really positive note by generating record revenue and gross margin performance, and our four business segments are hitting on all four cylinders. I'd like to point out that none of this would be possible without the tireless work of our dedicated team. I wanna end by thanking all of the employees as well as the patients and the stakeholders for their continued support. With that, I'd like to end the comments and open the line up for questions.
Okay. Again, if you'd like to ask a question, press star one. It looks like we have a question from Ross Osborn from Cantor. Your line is open.
Hi, guys. Congrats on the strong Q1. Thanks for taking our questions.
Thanks, Ross.
Maybe starting off, just would be curious to hear, the rationale for not providing revenue guidance at this point.
Well, Ross, you know, we're, you know, we're very pleased with the growth that we saw in Q1. We feel like we're on a good trajectory in really all parts of our business. The fact that we've recently implemented the couple of partnerships that we talked about, the deal with Sientra and the deal with LeMaitre, make it a little bit harder to just predict within a reasonable range, reasonably tight range, exactly what the future revenues will be. We feel like they're headed in the right direction. Importantly, in both cases, we feel like both those deals will really contribute more beneficially to the bottom line than if we were trying to do all of the sales ourselves. You know, we'll continue to evaluate that over the next quarter or two.
As we get a little bit of a trajectory going with both those partners as well as our own organization, in its new form, we'll reconsider whether it makes sense to do that in future quarters.
Okay, fair enough. I guess I realize it's only been 20 days or so since your partnership announcement with LeMaitre. Have you seen an increase in productivity of your sales force, with respect to CanGaroo, given it's their focus now? Do you plan to add to your direct team there?
So right now, our direct team there and our sales and commercial leadership is really focused on training and training their sales team and on account conversion where it makes sense for LeMaitre to, you know, to have complete access to the account. So we're looking right now to make sure that all of the customer and all of the revenue base we have transfers over completely and then have them build on that moving forward. So 20 days in, yeah, you got way too early for us, you know, to see anything directly out of the gate. I will say this, though.
This is a really solid partner, and this is a partner that we communicate with on a daily basis, you know, both at the team member level and at the leadership level. I think both. It's the answer, by the way. Both organizations, these partnerships are really important to both of us. Their success is really important to both of us. We really couldn't be more pleased with how either one of these has started out so far.
Okay, great. Lastly, maybe on burn. Following your cost reduction measures announced with 4Q results and, kind of the sales force changes with the partnerships, you know, how should we expect burn to decrease from here? You know, how much of the cost reduction initiatives were reflected in 1Q results?
Yeah. Actually, it's a good question, Ross. In the Q1, you know, the changes that we made really were enacted very close to the end of the quarter. you know, we talked about them then on our call for Q4, which is not until late in the quarter during Q1. you know, some of the cost of those changes will actually add to some of the expense in Q2. Other changes that we made will see a more immediate effect. I would say the overall effect in Q2 will be a little bit more muted, but we do expect cash burn to come down in Q2.
You know, rather than the $5 million that we saw in the last quarter and pretty consistently in the few quarters before that, you know, it's probably more like in the $3 million-$4 million range in the Q2. As we get into Q3 and Q4, we should see the full benefit of the changes. And we'll also start to see some of the, I think, increased productivity that you referred to before associated with some of these partnerships. Those will really hit, I'd say, in Q3 and Q4. You know, at that point, I would expect our cash burn to be, you know, down significantly from where it's been in the past. You know, as I mentioned in the prepared remarks, we would expect it to be about half of the $5 million level.
In other words, in the $2 million-$3 million per quarter range.
Okay, great. Thanks for taking my questions and congrats again on the strong quarter.
Ross.
Okay. Thanks, Ross.
That was our last question, ladies and gentlemen. This does conclude today's teleconference. We thank you for your participation. You may now disconnect your lines at this time.